Xingxiang Pu

机构：Central South University, Hunan Cancer Hospital · ORCID：0000-0002-2743-7080

发表论文 143 篇 · 总被引 1935 次 · h-index 24

代表论文

• Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial (2025 · The Lancet · 被引 33)
• PAM-Independent CRISPR-Cas12a System for Specific Assays of Single Nucleotide Variants (2025 · JACS Au · 被引 27)
• Cold beer-inspired multifunctional nanozyme for ischemic stroke with rapid thrombus clearance and long-lasting hydrogen therapy (2025 · Nano Today · 被引 15)
• SrAl 2 O 4 : Eu 2+ , Dy 3+ mechanoluminescent phosphor for potential bearings stress distribution imaging (2025 · Journal of the American Ceramic Society · 被引 12)
• Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced Non‐Small Cell Lung Cancer: Efficacy, Challenges, and Future Perspectives (2025 · Thoracic Cancer · 被引 7)
• Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration (2025 · Cancer Biology and Medicine · 被引 7)